Daiichi Sankyo has signed a new agreement with Max Planck Innovation and Lead Discovery Center to form a new cancer research collaboration.

As part of the partnership, Daiichi Sankyo will receive exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center.

The collaboration is built on biology insights in the field of transcriptional regulation from the work of professor Matthias Geyer at the Max Planck Institute of Molecular Physiology in Dortmund, Germany, and the Research Center caesar (Center of Advanced European Studies and Research) in Bonn, Germany.

Together with the Lead Discovery Center’s strong drug discovery expertise in the design of highly selective kinase inhibitors, the researchers from the three organisations will cooperate to further optimise the development of new compounds that target cancer cell transcription and proliferation.

"The three organisations will cooperate to further optimise the development of new compounds that target cancer cell transcription and proliferation."

Daiichi Sankyo Oncology Research and Development executive vice-president and global head Dr Antoine Yver said: “It is a great pleasure for us to start this research collaboration with Max Planck Innovation and the Lead Discovery Center to further generate innovation for our cancer drug discovery efforts."

Max Planck Society, supported by Max Planck Foundation, and Daiichi Sankyo will jointly fund the drug discovery efforts at the Lead Discovery Center.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Daiichi Sankyo also has the exclusive rights to licence the programme at pre-defined terms for subsequent preclinical and clinical development.

In the future, the three organisations aim to further enhance their partnership into additional drug development programmes.